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In 191 1, the first retrovirus was described: the Rous sarcoma virus, an avian retrovirus. Forty
years later the murine leukemic virus, a mouse retrovirus, was reported. Although many other
retroviruses from non-primate species were identified during the 1960s, the first primate
retrovirus was not recognized until it was isolated from a monkey tumor in 1970. The search for
human retroviruses in human leukemic cells remained unsuccessful at that time.
Facilitated by the discovery of T-cell growth factor, a substance used for the propagation of
human leukocytes in cultures, the first human retrovirus was discovered in 1980. Soon thereafter,
in 1983, another human retrovirus, human immunodeficiency virus (HIV), was reported and
implicated as the etiologic agent ofAIDS. The isolation and identification ofHIV has stimulated
much interest in the study ofhuman retroviruses and the control ofthis new viral disease.
HISTORICAL BACKGROUND
Retroviruses ofAnimals
Although the name retrovirus was not used at the time, the first retrovirus
characterized was the Rous sarcoma virus which caused tumors in chickens [1]. Forty
years later, Gross reported that an agent in cell-free extracts, now known to have been
a retrovirus, could induce leukemia in infant mice [2]. The latter report initiated many
subsequent studies on murine retroviruses, which have been reviewed elsewhere [3]. It
was not until the 1960s that retroviruses of other species were discovered (refer to
Table 1). These include the feline leukemia virus [4], the bovine leukemia virus [5],
and many others from non-primate mammalian species [3,6]. The first non-human
primate retrovirus identified was the Mason Pfizer monkey virus (MPMV) which was
isolated from the mammary carcinoma of a rhesus monkey in 1970 [7]. In early
studies, these retroviruses were recognized and identified by biological transmission
and/or by morphological observation of virus particles in leukemic cells. Since
retrovirus particles were easily found in the leukemic cells ofchickens, mice [3,6], and
guinea pigs [8], a number ofinvestigators, including our own group at the West Haven
VA Hospital, had examined, without success, numerous samples of human leukemic
cells for human retroviruses. Therefore, it was postulated that human retroviruses
might be present in an incomplete form in human tissue, thereby remaining undetect-
able by electron microscopy.
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TABLE 1
Discovery of Retroviruses of Man and Animala
Date Reported Name of Retrovirus Investigator [Reference]
1911 Avian sarcoma virus Rous P [1]
1951 Murine leukemia virus Gross L [2]
1964 Feline leukemia virus Jarrett et al. [4]
1964 Bovine leukemia virus Dutcher et al. [5]
1970 Mason-Pfizer monkey virus Chopra and Mason [7]
(MPMV)
(First primate retrovirus)
1980 Human T-cell leukemia virus I Poiesz et al. [12]
(HTLV-I)
(First human retrovirus)
1982 Human T-cell leukemia virus II Kalyanaraman et al. [13]
(HTLV-II)
(Second human retrovirus)
1983 Lymphadenopathy-associated virus Barre-Sinoussi etal. [15]
(LAV)
(Third human retrovirus)
1984 Human T-lymphotropic retrovirus III Gallo et al. [16,17]
(HTLV-III)
(Third human retrovirus)
aFor details, see [21].
Reverse Transcriptase and Retroviruses
Early studies ofavian and murine retroviruses showed that the intracellular state of
these RNA viruses was an integrated DNA, called the proviral intermediate. Prior to
the discovery ofreverse transcriptase (RT), it was difficult to determine how an RNA
virus could take the form ofa DNA genome, a process known as reverse transcription
because it reverses the standard direction (DNA to RNA) of the flow of genetic
information, The discovery, however, of RNA-dependent DNA polymerase in virions
of retroviruses by Temin and Mizutani [9] and by Baltimore [10] in 1970 provided a
mechanism to support the existence of a proviral intermediate during the growth of
retroviruses. This enzyme, RT, transcribes the viral RNA into DNA, which can then
integrate into host DNA. Since RT is uniquely associated with the replication of
retroviruses, it provides a sensitive biochemical assay system for the detection of this
group ofviruses.
Discovery ofT-Cell Growth Factors andIsolation ofHuman Retroviruses
Numerous attempts to isolate human retrovirus from human leukemic cells were
hindered in part by difficulties encountered in growing human leukemic cells in
cultures. The discovery of T-cell growth factor (TCGF), now called interleukin-2
(IL-2), which allows fortheproductive growth ofTcells in cultures [11], wascrucial to
the subsequent isolation ofhuman retroviruses. The first human retrovirus, the human
T-cell lymphotropic virus (HTLV-I), was isolated from cultured leukemic cells
obtained from a patient with cutaneous T-cell lymphoma [12]. The second human
retrovirus, also a human T-cell lymphotropic virus (HTLV-II), was similarly isolated
from leukocyte cultures derived from a patient with hairy-cell leukemia [13]. With
these discoveries, an era ofhuman retrovirus research had begun.
506RETROVIRUSES AND AIDS
Discovery ofthe Human Immunodeficiency Virus
The causative agent ofAIDS is a human retrovirus now named human immunodefi-
ciency virus (HIV) [14]. Several isolates ofthis samevirus include the lymphadenopa-
thy-associated virus (LAV) [15], human T-cell lymphotropic virus III (HTLV-III)
[16,17], and the AIDS-related group of viruses (ARV) [18,19]. A combination of
techniques originally developed for the avian and murine retroviruses, together with
the successful growth ofhuman leukemia cells in culture, allowed for the isolation and
identification of this group of human retroviruses. Indeed, HIV was grown in human
T-lymphocytes stimulated by thegrowth factor IL-2, and its presence was identified by
the RT assay method. Unlike most of the mammalian retroviruses, the RT assay for
HIV prefers Mg"+ over Mn"+ for its catalytic activities [20].
Montagnier and colleagues first reported in 1983 on the isolation ofan AIDS virus.
Because the isolate had been obtained from a patient with lymphadenopathy
syndrome, the virus was originally named lymphadenopathy-associated virus (LAV)
[15]. Simultaneously, Gallo and colleagues concentrated their efforts on establishing
cell lines for propagating retrovirus and identification of isolates obtained from AIDS
patients [16,17]. Isolates obtained by the latter studies were reported as human T-cell
lymphotropic virus III (HTLV-III). The establishment of a cell line, H9, from a
leukemia patient facilitated the propagation of the virus and the production of large
quantities of human retroviruses [16]. Large-scale production of HIV permitted the
development of serologic tests for screening blood samples, the production of mono-
clonal antibody for epidemiological surveys, and the preparation of cloned DNA
probes for studying the molecular mechanisms ofthe human retrovirus infection. The
chronological history ofthe discovery of human retroviruses and the demonstration of
AIDS as a retroviral disease has been detailed in a recent report [21].
RETROVIRUS CLASSIFICATION AND PROPERTIES
Classification ofRetroviruses
ThefamilyofRetroviridae consists ofRNAviruses that infect man and animals and
replicate through a DNA intermediate-the proviral DNA. The virion has a diameter
of 100 nm with a lipid bilayer envelope which surrounds an icosahedral corecontaining
a helical nucleocapsid (Fig. 1). The retrovirus family comprises three subfamilies
(Table 2), the Oncovirinae (RNA tumor virus group), the Spumavirinae (foamy virus
group), and the Lentivirinae (slow virus group). Within the lentivirus subgroup, HIV
shows a closer relationship with equine infectious anemia virus (EIAV) than withvisna
virus or caprine arthritis encephalitis virus (CAEV) [22].
Retroviruses can exist endogenously; that is, the virus is transmitted vertically from
generation to generation. For example, the guinea pig retrovirus, being endogenous,
can be activated in cultured cells by chemical induction [8,23]. On the other hand, an
exogenous retrovirus, for example HIV, is transmitted horizontally from infected
individuals to uninfected susceptible hosts.
Morphology ofHIV
Members of the HIV group are morphologically similar to other members of the
Retroviridae[24,25]. As with other retroviruses, HIV particles are formed by budding
through cytoplasmic membranes (Fig. 2A-2C). During in vitro cultivation of HIV in
the H9 cell line, budding virus particles are observed three to four days post-infection,
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FIG. 1. Schematic diagram of a
human immunodeficiency virus (HIV).
TABLE 2
The Retroviridae Family and Representative Virus Strains
Subfamily Virus Strain Vertebrale Host
Oncovirinaea (RNA tumor virus group)
Group B Mouse mammary tumor virus (MMTV) Mice
Group C Avian sarcoma virus (ASV) Chicken
Murine leukemia virus Mice
Feline leukemia virus Cats
Bovine leukemia virus Cattle
Human T-cell leukemia virus-I Human
Human T-cell leukemia virus-II Human
Group D Mason-Pfizer monkey virus Monkey
Ungroupedb Guinea pig leukemia virus Guinea pigs
Spumavirinae (foamy virus group)
Simian foamy virus Monkey
Human foamy virus Human
Feline syncytial virus Cats
Bovine syncytial virus Cattle
Lentivirinae (slow virus group)
Visna/maedi virus Sheep
Equine infectious anemia virus Horse
Caprine arthritis encephalitis virus Goat
Human immunodeficiency virus-I (HIV-I)
Lymphadenopathy-associated virus (LAV-1) Human
Human T-lymphotropic retrovirus III (HTLV-III) Human
AIDS-associated retrovirus (ARV) Human
Human immunodeficiency virus-2 (HIV-2)
Lymphadenopathy-associated virus (LAV-2) Human
Simian T-cell lymphotropic virus-III (STLV-III) Monkey
Human T-cell lymphotropic virus IV Human
aMorphologically, "A" type virus particles are commonly found intracellularly and are considered to be
immature virus particles.
bSee[8,23].
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FIG. 2. Electron micrographs showingdifferent stagesofHIVbuddingfrom the H9cells, sevendays
after infection. Bar (A-D) represents 0.1Iu. A. Early state ofbudding, thickening ofplasma membrane
(long arrows). B. Formation of crescent-shaped bands (long arrows). C. Appearances of intermediate
electron-lucent incomplete virus particles. D. Numerous extracellularvirus particles with electron-dense
cores; some are in the process ofpinching off(short arrow).
at which time RT is first detected. Intracellular virus particles are not found, although
extracellular mature virus particles, 100 nm in diameter, are scattered around the
infected cell and are easily identified after seven to ten days ofin vitrocultivation (Fig.
2D). The virus particles contain either a central or an eccentric dense core with or
without a characteristic bar-shaped band (Fig. 3A). Spikes on the enveloped viral
surfaces are not easily identified [20,24]. We have, however, recently found that these
surface projections were clearly seen (Fig. 3B) when the infected cells were post-fixed
in osmium tetroxide solution containing potassium ferrocyanide, a mixture previously
used for preservation ofmembranes, especially glycogen membranes [26]. Similar but
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v *.. Fn .IG. 3. Mature virus
particles seen extracellularly
at higher magnification. Bar
I represents 0.2 ~t. A. Sample
was fixed in 1 percent 0S04;
virus particles with bar-
shaped bands (BN), eccen-
tric (E), and central (C),
dense cores. B. Sample was
fixed in 1 percent 0S04 con-
tamning 2.5 percent potasium
A-~~~~~~~~ ~~~~ ~ferrocyanide; club-shaped A 4~~~~~~~~~~~~ ~~projections were seen sur-
~~ ~~~ ~~~ ~~~ rounding each virus particle.
less distinct projections were visible on virus particles in thin sections of HIV-infected
cells treated with tannic acid prior to embedding [25].
Viral Genome and Viral Protein ofHIV
The genomic organization of HIV, like other retroviruses, includes long terminal
repeats (LTR) at both the 5' and 3'ends, thegroup-specific gene (gag), the polymerase
gene (pol), and the envelope gene (env). In addition, HIV contains four other genes:
the transactivating element (tat), the translational controller (trs/art), the short open
reading frame (sor), and another open reading frame (orf). These last four genes
encode proteins that help to control the expression of HIV [27]. A schematic diagram
of the HIV genome and protein products is illustrated in Fig. 4. The major core
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FIG. 4. Schematic diagram of a HIV genome structure and protein products: long terminal repeats
(LTR); three retrovirus genes: group-specific gene (GAG), polymerase gene (POL), and envelope gene
(ENV); and four other HIV genes: transactivating element (TAT), translational controller (TRS), short
open reading frame (SOR), and another open reading frame (ORF).
proteins are p24 and p18. The bilayer envelope is studded with glycoproteins. The
major glycoproteins ofthe envelope gene are gp41 and gpl20 (see Figs. 1 and 4). Sera
from AIDS patients with advanced disease sometimes show greatly diminished
intensity to the p24 protein band when compared with sera from pre-AIDS patients
[28,29]. Therefore, the measurement of antibody to p24 protein has been used as a
convenient indicator regarding the stage ofthe disease in AIDS patients.
LABORATORY DIAGNOSIS OF HIV INFECTION
Serologic TestsforHIVAntibody
Since 1984 there has been a steady and rapid increase in knowledge about the
pathogenesis of HIV infection. Early studies showed that antibodies to HIV were
present in close to 90 percent ofAIDS patients and in more than 75 percentofpatients
with pre-AIDS syndromes [30]. Since May 1985, commercially licensed enzyme-
linked immunosorbent assay (ELISA) kits have been used for testing blood or plasma
from normal blood donors for HIV antibody [30-33]. These tests are now accepted as
having good sensitivity and specificity for screening blood donors. Their use has
resulted in the almost complete elimination of HIV-contaminated blood or blood
products from the nation's blood supply and have rendered transfusion much safer.
Because the ELISA test was originally developed for screening the blood ofdonors,
however, these tests are very sensitive, and false-positive reactions have been noted
[32]. Therefore, all sera reacting positively by ELISA tests must be confirmed by
other, more specific techniques; e.g., the Western blot immunoassay [34,35] or by
immunofluorescence [36]. Some false positives have been found to be due to human
leukocyte antigen (HLA) present in HIV reagent prepared from H9 cells [37-42]. As
is the case with otherviral infections, isolation and identification ofthe infectious agent
permit a definitive and specific diagnosis.
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HIVIsolation andIdentification
Although serodiagnosis is now widely used for detecting HIV infection, none ofthe
tests currently available are able to differentiate perfectly infected from non-infected
individuals. Isolation of HIV from clinical specimens, though tedious and time-
consuming, offers the advantage of confirmation that the person is actually infected
with HIV. General principles and detailed procedures for the isolation and identifica-
tion of HIV are included in the paper by Griffith in this issue [43], and many more
techniques are expected to bedeveloped in the years to come. As easier and more rapid
methods become available for the isolation and cultivation of this virus, the virology
laboratory service will play a larger role in the management of HIV-infected
individuals.
Significance ofLaboratory Diagnosis
HIV has been isolated from blood [15-19] and other body fluids ofinfected patients
including semen, vaginal secretions, tears, saliva, breast milk, and cerebrospinal fluid
[44-51]. Transmission ofHIV bysexual contact with infected individuals, by receiving
contaminated blood or blood products, or by perinatal exposure of children born to
infected mothers is well documented [52-55]. Many individuals may be infected with
the virus for years without showing any signs or symptoms and yet can transmit the
virus toothers by blood donation orby sexual contact. Thus, laboratory testing for HIV
infection should be helpful, especially with the high-risk groups, in preventing further
transmission ofthis viral disease.
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